Auron Therapeutics, Inc.

We’re honored to be supported by The Leukemia & Lymphoma Society through their prestigious Therapy Acceleration Program® (TAP)! LLS TAP’s investment in Auron supports the rapid development of our Phase 1 AUTX-703 for relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. This partnership brings more than funding – we gain access to LLS’s unparalleled expertise in blood cancer research and their deep understanding of patient needs. Together, we’re working to bring transformative therapies to patients who need them most. #Biotechnology #BloodCancer #AML #ClinicalTrials #DrugDevelopment

We’re thrilled to announce a major milestone for Auron Therapeutics: the first patient has been dosed in our Phase 1 clinical trial of AUTX-703 for advanced hematologic malignancies! AUTX-703, our first-in-class oral KAT2A/B degrader, represents a novel approach to targeting cell-state plasticity in cancer. This groundbreaking therapeutic was discovered and developed using our proprietary AURIGIN™ platform. This moment marks our transition to a clinical-stage company and brings us one step closer to our mission of delivering transformative therapies for patients with limited treatment options. #ClinicalTrials #Oncology #AML #HematologicMalignancies #DrugDevelopment

We’re thrilled to announce a major milestone for Auron Therapeutics: the first patient has been dosed in our Phase 1 clinical trial of AUTX-703 for advanced hematologic malignancies! AUTX-703, our first-in-class oral KAT2A/B degrader, represents a novel approach to targeting cell-state plasticity in cancer. This groundbreaking therapeutic was discovered and developed using our proprietary AURIGIN™ platform. This moment marks our transition to a clinical-stage company and brings us one step closer to our mission of delivering transformative therapies for patients with limited treatment options. https://lnkd.in/eYR_Pb5m #ClinicalTrials #Oncology #AML #HematologicMalignancies #DrugDevelopment

We’re thrilled to have shared our latest preclinical findings on AUTX-703 yesterday at #AACR2025 in Chicago! Our poster presentation highlighted how our oral KAT2A/B degrader demonstrates promising activity in multiple prostate cancer sub-types. The data presented represent an important finding in our mission to address cancer cell-state plasticity and provide new options for types of cancer. As we prepare to initiate our Phase 1 clinical trial in hematologic malignancies, we’re excited about AUTX-703’s potential to transform the treatment landscape for patients with limited options. Thank you to everyone who visited our poster and engaged with our team. https://lnkd.in/eJXFvADr #CancerResearch #DrugDiscovery #PreclinicalData #ProstateCancer

We’re thrilled to share new preclinical data for AUTX-703 in Small Cell Lung Cancer (SCLC) presented at the #SCLC25 Hot Topic Meeting in New York. As we advance our Phase 1 trial in hematologic malignancies, this preclinical data supports the potential of targeting cell-state plasticity in multiple tumor types. https://lnkd.in/e4wmMpcN #Cancer #DrugDiscovery #Oncology #BiotechInnovation

We’re excited to present a poster at the upcoming #AACR2025 Annual Meeting in Chicago. We look forward to sharing new preclinical data from our lead program, AUTX-703, an oral, potent and selective degrader targeting KAT2A/B. https://lnkd.in/epRiQxmZ #CancerResearch 

We’re excited to welcome @Glenn Goddard as our new Chief Financial Officer! With over 25 years of biotech finance leadership and experience, Glenn joins us at a critical time as we prepare to enter the clinic with our lead program AUTX-703. Join us in welcoming Glenn to the Auron team! https://lnkd.in/eUD9Msw3 #Biotech #Leadership

"You can have the best drug in the world, but if you don't know how to use it, it's not gonna help you." In Part 2 of The Biotech Startups Podcast conversation with Auron Therapeutics, Inc. Founder & CEO Kate Yen, a central theme revolves around marrying deep biological insight with clinical execution to maximize therapeutic impact. – From lab bench to bedside: Kate’s journey leading Agios’ IDH inhibitor program, where biomarker development and mechanistic studies became the backbone of clinical trial design – Avoiding the "over-the-wall" trap: Why translational biology must run parallel to drug discovery from day 1 to inform physician use cases – Clinical trial optimization: Partnering with regulators early and using biomarker-driven patient stratification to reduce costs while improving outcomes – Platforms with purpose: How Auron’s differentiation-focused approach and developmental biology atlas aim to rewrite cancer treatment paradigms – Resourceful company-building: Launching a lean biotech through strategic CRO partnerships and shared lab spaces while keeping science front-and-center This episode crackles with hard-won insights about bridging discovery and clinical impact – including how Kate’s team achieved FDA approvals using phase 1 data. Head over to Apple Podcasts or Spotify for this episode and more stories only a biotech exec can tell! #biotechnology #lifesciences #podcast

We're excited to share that we've received Fast Track Designation in AML! https://lnkd.in/e-JYPBdP

Check out Part 1 of our CEO @Kate Yen’s conversation on The Biotech Startups Podcast. Dive into Kate’s insights into the power of collaboration in biotech, her journey from academia to industry, and how embracing diverse perspectives drives innovation in drug development. Listen to the full episode on Apple Podcasts or Spotify! #biotechnology #lifesciences #drugdevelopment